Melatonin reduces phenylhydrazine-induced oxidative damage to cellular membranes: Evidence for the involvement of iron

Małgorzata Karbownik, Russel J Reiter, Joaquin J. Garcia, Dun Xian Tan

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Phenylhydrazine and iron overload result in augmented oxidative damage and an increased likelihood of cancer. Melatonin is a well known antioxidant and free radical scavenger. The aim of this study was to determine whether melatonin would protect against phenylhydrazine-induced oxidative damage to cellular membranes and to evaluate the possible role of iron in this process. Changes in lipid peroxidation and microsomal membrane fluidity were estimated after the treatment of rats with phenylhydrazine (15 mg/kg body weight, daily, 7 days) alone and melatonin or ascorbic acid (15 mg/kg body weight, two times daily, 8 days), or their combination. Additionally, lipid peroxidation was measured in liver homogenates from untreated and melatonin or ascorbic acid-treated rats in vivo and exposed to iron in vitro. Melatonin, but not ascorbic acid, reduced phenylhydrazine-induced lipid peroxidation in vivo in spleen (3.16 ± 0.06 vs. 3.83 ± 0.12 nmol/mg protein, P < 0.05) and plasma (7.73 ± 0.52 vs. 9.96 ± 0.71 nmol/ml, P < 0.05) and attenuated the decrease in hepatic microsomal membrane fluidity (1/polarization, 3.068 ± 0.007 vs. 3.027 ± 0.008, P < 0.05). In vitro exposure to iron significantly enhanced the lipid peroxidation in liver homogenates from untreated (3.34 ± 0.75 vs. 1.25 ± 0.28, P < 0.05) or ascorbic acid-treated rats (2.72 ± 0.39 vs. 0.88 ± 0.06, P < 0.05) but not from melatonin-treated rats (1.49 ± 0.55 vs. 0.68 ± 0.20, NS). It is concluded that free radical mechanisms are involved in the toxicity of phenylhydrazine and that the antioxidant melatonin, but not ascorbic acid, reduces the toxic affects of phenylhydrazine in vivo and of iron in vitro in cell membranes. Therefore, melatonin co-treatment in conditions of iron overload may prove beneficial. (C) 2000 Elsevier Science Ltd.

Original languageEnglish (US)
Pages (from-to)1045-1054
Number of pages10
JournalInternational Journal of Biochemistry and Cell Biology
Volume32
Issue number10
DOIs
StatePublished - 2000

Fingerprint

Melatonin
Iron
Membranes
Ascorbic Acid
Lipid Peroxidation
Rats
Lipids
Membrane Fluidity
Iron Overload
Fluidity
Liver
Antioxidants
Body Weight
Free Radical Scavengers
phenylhydrazine
Poisons
Cell membranes
Free Radicals
Toxicity
Spleen

Keywords

  • Cancer
  • Iron
  • Melatonin
  • Membrane oxidative damage
  • Phenylhydrazine

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

Melatonin reduces phenylhydrazine-induced oxidative damage to cellular membranes : Evidence for the involvement of iron. / Karbownik, Małgorzata; Reiter, Russel J; Garcia, Joaquin J.; Tan, Dun Xian.

In: International Journal of Biochemistry and Cell Biology, Vol. 32, No. 10, 2000, p. 1045-1054.

Research output: Contribution to journalArticle

@article{5cc208436b2f43259ca597a072325034,
title = "Melatonin reduces phenylhydrazine-induced oxidative damage to cellular membranes: Evidence for the involvement of iron",
abstract = "Phenylhydrazine and iron overload result in augmented oxidative damage and an increased likelihood of cancer. Melatonin is a well known antioxidant and free radical scavenger. The aim of this study was to determine whether melatonin would protect against phenylhydrazine-induced oxidative damage to cellular membranes and to evaluate the possible role of iron in this process. Changes in lipid peroxidation and microsomal membrane fluidity were estimated after the treatment of rats with phenylhydrazine (15 mg/kg body weight, daily, 7 days) alone and melatonin or ascorbic acid (15 mg/kg body weight, two times daily, 8 days), or their combination. Additionally, lipid peroxidation was measured in liver homogenates from untreated and melatonin or ascorbic acid-treated rats in vivo and exposed to iron in vitro. Melatonin, but not ascorbic acid, reduced phenylhydrazine-induced lipid peroxidation in vivo in spleen (3.16 ± 0.06 vs. 3.83 ± 0.12 nmol/mg protein, P < 0.05) and plasma (7.73 ± 0.52 vs. 9.96 ± 0.71 nmol/ml, P < 0.05) and attenuated the decrease in hepatic microsomal membrane fluidity (1/polarization, 3.068 ± 0.007 vs. 3.027 ± 0.008, P < 0.05). In vitro exposure to iron significantly enhanced the lipid peroxidation in liver homogenates from untreated (3.34 ± 0.75 vs. 1.25 ± 0.28, P < 0.05) or ascorbic acid-treated rats (2.72 ± 0.39 vs. 0.88 ± 0.06, P < 0.05) but not from melatonin-treated rats (1.49 ± 0.55 vs. 0.68 ± 0.20, NS). It is concluded that free radical mechanisms are involved in the toxicity of phenylhydrazine and that the antioxidant melatonin, but not ascorbic acid, reduces the toxic affects of phenylhydrazine in vivo and of iron in vitro in cell membranes. Therefore, melatonin co-treatment in conditions of iron overload may prove beneficial. (C) 2000 Elsevier Science Ltd.",
keywords = "Cancer, Iron, Melatonin, Membrane oxidative damage, Phenylhydrazine",
author = "Małgorzata Karbownik and Reiter, {Russel J} and Garcia, {Joaquin J.} and Tan, {Dun Xian}",
year = "2000",
doi = "10.1016/S1357-2725(00)00056-X",
language = "English (US)",
volume = "32",
pages = "1045--1054",
journal = "International Journal of Biochemistry and Cell Biology",
issn = "1357-2725",
publisher = "Elsevier Limited",
number = "10",

}

TY - JOUR

T1 - Melatonin reduces phenylhydrazine-induced oxidative damage to cellular membranes

T2 - Evidence for the involvement of iron

AU - Karbownik, Małgorzata

AU - Reiter, Russel J

AU - Garcia, Joaquin J.

AU - Tan, Dun Xian

PY - 2000

Y1 - 2000

N2 - Phenylhydrazine and iron overload result in augmented oxidative damage and an increased likelihood of cancer. Melatonin is a well known antioxidant and free radical scavenger. The aim of this study was to determine whether melatonin would protect against phenylhydrazine-induced oxidative damage to cellular membranes and to evaluate the possible role of iron in this process. Changes in lipid peroxidation and microsomal membrane fluidity were estimated after the treatment of rats with phenylhydrazine (15 mg/kg body weight, daily, 7 days) alone and melatonin or ascorbic acid (15 mg/kg body weight, two times daily, 8 days), or their combination. Additionally, lipid peroxidation was measured in liver homogenates from untreated and melatonin or ascorbic acid-treated rats in vivo and exposed to iron in vitro. Melatonin, but not ascorbic acid, reduced phenylhydrazine-induced lipid peroxidation in vivo in spleen (3.16 ± 0.06 vs. 3.83 ± 0.12 nmol/mg protein, P < 0.05) and plasma (7.73 ± 0.52 vs. 9.96 ± 0.71 nmol/ml, P < 0.05) and attenuated the decrease in hepatic microsomal membrane fluidity (1/polarization, 3.068 ± 0.007 vs. 3.027 ± 0.008, P < 0.05). In vitro exposure to iron significantly enhanced the lipid peroxidation in liver homogenates from untreated (3.34 ± 0.75 vs. 1.25 ± 0.28, P < 0.05) or ascorbic acid-treated rats (2.72 ± 0.39 vs. 0.88 ± 0.06, P < 0.05) but not from melatonin-treated rats (1.49 ± 0.55 vs. 0.68 ± 0.20, NS). It is concluded that free radical mechanisms are involved in the toxicity of phenylhydrazine and that the antioxidant melatonin, but not ascorbic acid, reduces the toxic affects of phenylhydrazine in vivo and of iron in vitro in cell membranes. Therefore, melatonin co-treatment in conditions of iron overload may prove beneficial. (C) 2000 Elsevier Science Ltd.

AB - Phenylhydrazine and iron overload result in augmented oxidative damage and an increased likelihood of cancer. Melatonin is a well known antioxidant and free radical scavenger. The aim of this study was to determine whether melatonin would protect against phenylhydrazine-induced oxidative damage to cellular membranes and to evaluate the possible role of iron in this process. Changes in lipid peroxidation and microsomal membrane fluidity were estimated after the treatment of rats with phenylhydrazine (15 mg/kg body weight, daily, 7 days) alone and melatonin or ascorbic acid (15 mg/kg body weight, two times daily, 8 days), or their combination. Additionally, lipid peroxidation was measured in liver homogenates from untreated and melatonin or ascorbic acid-treated rats in vivo and exposed to iron in vitro. Melatonin, but not ascorbic acid, reduced phenylhydrazine-induced lipid peroxidation in vivo in spleen (3.16 ± 0.06 vs. 3.83 ± 0.12 nmol/mg protein, P < 0.05) and plasma (7.73 ± 0.52 vs. 9.96 ± 0.71 nmol/ml, P < 0.05) and attenuated the decrease in hepatic microsomal membrane fluidity (1/polarization, 3.068 ± 0.007 vs. 3.027 ± 0.008, P < 0.05). In vitro exposure to iron significantly enhanced the lipid peroxidation in liver homogenates from untreated (3.34 ± 0.75 vs. 1.25 ± 0.28, P < 0.05) or ascorbic acid-treated rats (2.72 ± 0.39 vs. 0.88 ± 0.06, P < 0.05) but not from melatonin-treated rats (1.49 ± 0.55 vs. 0.68 ± 0.20, NS). It is concluded that free radical mechanisms are involved in the toxicity of phenylhydrazine and that the antioxidant melatonin, but not ascorbic acid, reduces the toxic affects of phenylhydrazine in vivo and of iron in vitro in cell membranes. Therefore, melatonin co-treatment in conditions of iron overload may prove beneficial. (C) 2000 Elsevier Science Ltd.

KW - Cancer

KW - Iron

KW - Melatonin

KW - Membrane oxidative damage

KW - Phenylhydrazine

UR - http://www.scopus.com/inward/record.url?scp=0033681047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033681047&partnerID=8YFLogxK

U2 - 10.1016/S1357-2725(00)00056-X

DO - 10.1016/S1357-2725(00)00056-X

M3 - Article

C2 - 11091137

AN - SCOPUS:0033681047

VL - 32

SP - 1045

EP - 1054

JO - International Journal of Biochemistry and Cell Biology

JF - International Journal of Biochemistry and Cell Biology

SN - 1357-2725

IS - 10

ER -